Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Metsera started by Guggenheim at buy on obesity drug opportunity
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Wall Street bullish on Metsera following January IPO on obesity drug pipeline
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
This weight-loss drug stock could deliver a 90% return in 2025
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Metsera initiated with a Buy at BofA
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
Metsera initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...
Pharm Exec8d
2025 Pipeline Report: The Edge of Greatness?
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...
BioSpace12d
Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
FierceBiotech13d
Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials
Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...
Exelixis stock holds firm with $41 target from JMP Securities
JMP Securities maintained a Market Outperform rating and a $41.00 price target for Exelixis (NASDAQ:EXEL) shares, aligning with the broader analyst consensus as five analysts have recently revised ...